Fiscal Year: January - December
Bristol-Myers Squibb Company (BMY), listed on the NYSE, has a market capitalization of $. As of Feb 22, 2026, the stock is trading at $60.66 per share, offering investors a clear view of its current market value. Bristol-Myers Squibb Company is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 17.53, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Bristol-Myers Squibb Company also offers a dividend yield of 4.15%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Bristol-Myers Squibb Company (BMY) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Bristol-Myers Squibb Company is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Bristol-Myers Squibb Company, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Bristol-Myers Squibb Company is 9.62, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Bristol-Myers Squibb Company (BMY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Bristol-Myers Squibb Company (BMY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Bristol-Myers Squibb Company (BMY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Bristol-Myers Squibb Company. To access the full SS Score, consider upgrading your subscription.
Bristol-Myers Squibb Company is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 17.53. Investors should compare these metrics with industry peers to gauge whether Bristol-Myers Squibb Company is outperforming or underperforming within its sector.
Bristol-Myers: I'm Buying Post Earnings
Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favo...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Relapsed or Refractory Multiple Myeloma.
Markets in 2026 are rewarding selectivity rather than size alone. Mega-cap leadership has narrowed, volatility has resurfaced, and investors are searching for a framework that can adapt to rotation. A...
BAAR, Switzerland--(BUSINESS WIRE)--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence.
Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with ma...
Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
Bristol Myers Squibb & Co. (NYSE:BMY) reported better-than-expected results for the fourth quarter.
Bristol Myers Squibb & Co. (NYSE: BMY) reported fourth-quarter 2025 revenues of $12.50 billion on Thursday, beating the consensus of $12.281 billion, a 1% increase year over year.
Bristol Myers Squibb issues an especially upbeat outlook for 2026.
Bristol Myers Squibb reported higher fourth-quarter revenue as growth in sales of its immuno-oncology treatments helped to offset a decline in revenue for some of its older drugs.
Bristol Myers Squibb on Thursday forecast 2026 results above Wall Street estimates, saying that price cuts to its blood thinner Eliquis will help drive up revenue.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025.
Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has expanded its strategic partnership with Bristol Myers Squibb (“BMS”...
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.
Bristol Myers Squibb (BMY) has delivered a ~27% total return in three months, driven by topline growth and dividend strength. With the valuation rebound largely complete, BMY shifts from a high-convic...
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter...
Janux Therapeutics, Inc. (NASDAQ: JANX) on Thursday announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb Co. (NYSE: BMY).
Janux Therapeutics said on Thursday it has entered a collaboration with Bristol Myers Squibb to develop a new cancer treatment, sending its shares up more than 12% in premarket trading.
Stocks entered 2026 on a positive note before a global sell-off wiped out gains, driven by tariff tensions, a Greenland tug-of-war, and Japan's bond crisis. In this uncertain environment, dividends ca...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 15.84B | Analyst x4 | |
| 2027 | 14.34B | -9.47% | Analyst x6 |
| 2028 | 13.67B | -4.67% | Analyst x5 |
| 2029 | 12.50B | -8.54% | Analyst x5 |
| 2030 | 12.03B | -3.78% | Analyst x5 |
| 2031 | 11.90B | -1.10% | Est @-1.1% |
| 2032 | 11.90B | 0.00% | Est @0.0% |
| 2033 | 11.99B | 0.76% | Est @0.8% |
| 2034 | 12.13B | 1.22% | Est @1.2% |
| 2035 | 12.33B | 1.57% | Est @1.6% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 13.94B | 1.00 | 13.94B |
| 2025A | 12.85B | 1.00 | 12.85B |
| 2026E | 15.84B | 1.08 | 14.72B |
| 2027E | 14.34B | 1.16 | 12.39B |
| 2028E | 13.67B | 1.25 | 10.97B |
| 2029E | 12.50B | 1.34 | 9.33B |
| 2030E | 12.03B | 1.44 | 8.34B |
| 2031E | 11.90B | 1.55 | 7.67B |
| 2032E | 11.90B | 1.67 | 7.12B |
| 2033E | 11.99B | 1.80 | 6.67B |
| 2034E | 12.13B | 1.93 | 6.28B |
| 2035E | 12.33B | 2.08 | 5.92B |
| Terminal | 247.60B | 2.08 | 118.99B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
